Investor brief
One focused
validation program.
Pre-seed capital to test a cardio-renal tissue-system concept against a real partner question—and establish whether the evidence supports a paid pilot.
Start an investment conversation ↗Pre-seed validation capital
Cardio-renal translational R&D
TRL 2 · no integrated experimental proof of concept
Corelia Bio’s first planned evidence package targets CKD-driven cardiac injury and fibrosis. The proposed approach combines engineered human tissues, defined stress conditions and paired functional, structural and molecular readouts.
Intended use of capital
- Define the first context of use with design partners.
- Establish baseline tissue-module robustness.
- Test a reproducible disease phenotype and intervention response.
- Develop a partner-ready evidence package and a scoped paid pilot.
The detailed budget, sequencing and pilot terms are subject to scientific scope and financing.
Target milestones—not completed traction
The path to a first paid pilot.
- 15–20
Discovery interviews
Define a decision worth supporting.
- 2
Written partner scopes
Agree intended use and study boundaries.
- 1
Evidence package
Evaluate technical acceptance criteria.
- ≥1
Structured paid pilot
Test commercial relevance.
First physical evidence package targeted for Q1 2027, subject to funding, partner scope and experimental readiness.
Founder experience
Ronald St-Louis, PhD, brings 12+ years across kidney and cardiometabolic research, fibrosis and drug discovery. Prior experience includes Harvard / Joslin Diabetes Center, OVIBIO and Evotec.
Ecosystem participation
Corelia Bio has participated in ELSA 2026 and the Life Science Factory Göttingen community, with visibility through InnoMatch Niedersachsen.
Corelia Intelligence
Corelia Bio also operates Corelia Intelligence (opens in a new tab), an AI-based research workspace that turns cardio-renal evidence into reviewable decision dossiers. It extends the HETS™ program on the evidence side and supports question framing ahead of partner studies.
What remains to be established
Integrated experimental feasibility, reproducibility, disease specificity, translational relevance and willingness to pay. These are the questions the proposed validation program is designed to address.
Advisory needs
Corelia Bio is seeking one or two biotech/pharma business-development advisors alongside strategic design partners.